Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2019 | NSCLC: a treatment landscape in flux in the checkpoint inhibitor era

Martin Reck • 12 Apr 2019
ELCC 2019
Lung Cancer Non-Small Cell Lung Cancer Checkpoint Inhibitors Durvalumab

The treatment landscape of non-small cell lung cancer (NSCLC) is in a state of flux, with novel immuno-oncology agents and combinations at the forefront. Here, Martin Reck, MD, PhD, from Lung Clinic Grosshansdorf, Grosshansdorf, Germany, gives his insight into this changing field and the future considerations. This interview took place at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.

More from Martin Reck

5:41
JAVELIN Lung100, PRIMUS, NintNivo, IMpower010: investigating IO in NSCLC
Martin Reck • 8 Aug 2022
2:35
Atezo maintenance therapy improves survival in the IMpower133 trial of ES-SCLC
Martin Reck • 1 Feb 2021
3:03
KEYNOTE-799: pembro + chemoradiotherapy in locally advanced NSCLC
Martin Reck • 1 Feb 2021
3:24
Pembro +/- ipi in metastatic NSCLC: KEYNOTE-598
Martin Reck • 1 Feb 2021

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals